Lilly's Weekly Insulin Wins US Approval for Type 2 Diabetes

Eli Lilly announced that its drug Onesik has secured official approval to serve as a basal insulin administered once weekly. The medication is indicated for adults living with type 2 diabetes and functions alongside diet and exercise regimens. This development follows regulatory clearance in the United States, offering patients who rely on daily long-acting insulin an alternative to frequent injections.

Reduction in Injection Frequency

The company states that this new treatment could decrease the number of annual injections by more than 300 compared to traditional insulin therapies. For individuals currently burdened by daily administration requirements, the shift to a weekly dosage represents a significant change in management protocols. The approval marks a notable advancement in therapeutic options available within the American market.

Clinical Evidence and Efficacy

Regulatory authorization came after a series of advanced studies involving more than 3,400 patients. These trials demonstrated positive results in lowering A1C levels, achieving effectiveness comparable to daily basal insulins such as glargine. Glargine has been utilized for years under various commercial names, including Lantus and Asaglar, to control blood sugar in both type 1 and type 2 diabetes cases.

Market Availability and Dosage Forms

Onesik is scheduled to enter the US market in the coming months. It will be distributed as a ready-to-use KwikPen device, available in two distinct concentrations: 500 units per milliliter and 1,000 units per milliliter. Eli Lilly emphasized that the drug is not suitable for patients with type 1 diabetes due to the risk of severe hypoglycemia, necessitating caution during use.

Global Regulatory Precedents

Prior to the US decision, the medication had already obtained regulatory approvals in Europe, Japan, and Mexico. These existing authorizations support expectations for broader global distribution in the near future. The drug aims to alleviate the daily treatment burden for millions of patients worldwide through its weekly administration schedule.